在线MR引导多分次立体定向消融放疗在肺部肿瘤中的作用
这项前瞻性观察研究纳入45例患者共59个病灶,评估在线自适应MR引导SBRT的剂量学获益、肺功能变化和临床结局。再优化计划使PTV处方剂量覆盖在94.6%的分次中提高,中位PTV VPD增加5.6%(p<0.001),PTV VPD≥95%的分次数从33%增至98%。中位随访21.4个月,1年和2年局部控制率分别为94.8%和91.1%,1年和2年总生存率分别为85.6%和67.1%,记录到1例≥3级毒性,短期肺功能参数无显著下降。
要点
- 再优化计划使PTV VPD≥95%的分次数从33%增至98%,中位PTV VPD增加5.6%(p<0.001)。
- 中位随访21.4个月,1年和2年局部控制率分别为94.8%和91.1%。
- 记录到1例≥3级毒性,短期肺功能参数无显著下降。
核心结论
- 在线自适应MR引导SBRT是肺部肿瘤有效、安全且总体耐受良好的治疗选择,局部控制率令人鼓舞,靶区覆盖显著改善。
研究设计与样本
- 前瞻性观察研究,2020年11月至2022年7月连续纳入45例患者共59个病灶,接受3-8分次SBRT。
- 入组条件为活检证实的NSCLC或经临床影像诊断的肺癌/转移瘤。
- 终点为局部控制(LC)和总生存(OS),评估PTV/GTV剂量覆盖、危及器官暴露和肺功能变化。
- 急性毒性按美国国家癌症研究所不良事件通用术语标准5.0版分级。
主要发现
- 中位PTV为14.4 cm3(范围3.4-96.5 cm3),195/215(91%)的计划被再优化。
- 再优化计划 vs 预测计划:PTV处方剂量覆盖在94.6%的分次中增加,中位PTV VPD增加5.6%(范围-1.8-44.6%,p<0.001)。
- 再优化计划 vs 预测计划:PTV VPD≥95%的分次数从33%增至98%。
- 再优化计划 vs 预测计划:PTV D95%和D98%(BED10)分别在93%和95%的分次中增加,中位增加7.7%(p<0.001)和10.6%(p<0.001)。
- PTV D95%(BED10)平均增加9.6 Gy(标准差10.3 Gy,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this prospective observational study was to evaluate the dosimetry benefits, changes in pulmonary function, and clinical outcome of online adaptive MR-guided SBRT. METHODS: From 11/2020-07/2022, 45 consecutive patients with 59 lesions underwent multi-fraction SBRT (3-8 fractions) at our institution. Patients were eligible if they had biopsy-proven NSCLC or lung cancer/metastases diagnosed via clinical imaging. Endpoints were local control (LC) and overall survival (OS). We evaluated PTV/GTV dose coverage, organs at risk exposure, and changes in pulmonary function (PF). Acute toxicity was classified per the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0. RESULTS: The median PTV was 14.4 cm3 (range: 3.4 - 96.5 cm3). In total 195/215 (91%) plans were reoptimised. In the reoptimised vs. predicted plans, PTV coverage by the prescribed dose increased in 94.6% of all fractions with a median increase in PTV VPD of 5.6% (range: -1.8 - 44.6%, p < 0.001), increasing the number of fractions with PTV VPD ≥ 95% from 33% to 98%. The PTV D95% and D98% (BED10) increased in 93% and 95% of all fractions with a median increase of 7.7% (p < 0.001) and 10.6% (p < 0.001). The PTV D95% (BED10) increased by a mean of 9.6 Gy (SD: 10.3 Gy, p < 0.001). At a median follow-up of 21.4 months (95% CI: 12.3-27.0 months), 1- and 2-year LC rates were 94.8% (95% CI: 87.6 - 100.0%) and 91.1% (95% CI: 81.3 - 100%); 1- and 2-year OS rates were 85.6% (95% CI: 75.0 - 96.3%) and 67.1 % (95% CI: 50.3 - 83.8%). One grade ≥ 3 toxicity and no significant reduction in short-term PF parameters were recorded. CONCLUSIONS: Online adaptive MR-guided SBRT is an effective, safe and generally well tolerated treatment option for lung tumours achieving encouraging local control rates with significantly improved target volume coverage.
引用
- Hering S, Nieto A, Marschner S, et al. The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours. Clin Transl Radiat Oncol. 2024. PMID: 38433949. doi:10.1016/j.ctro.2024.100736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。